Piper Sandler raised the firm’s price target on Inari Medical (NARI) to $80 from $52 and keeps a Neutral rating on the shares after the company agreed to be acquired by Stryker (SYK) for an enterprise deal value of $4.8B. The firm thinks the combination makes sense and provides Stryker with a nice complement to the company’s neuro franchise, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NARI:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue